Cancer BiologyCancer ResearchPeer-reviewed
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules
Phillip Thienger, Irene Paassen, Xiaosai Yao…·Mark A. Rubin
This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.
11 citationstop 1%